Medication Discovery Using Rat Models of Relapse. Period of Performance: 7/10/2019-7/9/2021. N01DA-19-8949

本合同的目的是确定新化合物在使用可卡因、尼古丁、甲基苯丙胺或阿片类药物的复发动物模型中的体内疗效。这包括在训练自我服用可卡因的动物中进行的以下测试（例如）：（1）测试化合物阻断足电击或其它应激物诱导的在实验性消退期后的反应恢复的能力;（2）测试化合物阻断或减少引发诱导的在消退期后的反应恢复的能力;和（3）测试化合物阻断条件提示（先前与训练药物配对）的作用以在消退期后恢复对训练药物的应答的能力。

The objective of this contract is to determine the in vivo efficacy of novel compounds in animal models of relapse using cocaine, nicotine, methamphetamine, or opioids. This includes the following tests in animals trained to self- administer cocaine (for example): (1) the ability of a test compound to block footshock or other stressor-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block or reduce priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with the training drug) to reinstate responding for the training drug after a period of extinction.